A Study to Determine Frequency of DNA-repair Defects in Men With Metastatic Prostate Cancer

  • STATUS
    Recruiting
  • End date
    Sep 16, 2023
  • participants needed
    10000
  • sponsor
    Janssen Research & Development, LLC
Updated on 8 January 2021
Investigator
The Medical Research Network, LLC
Primary Contact
Macquarie University Hospital (0.1 mi away) Contact
+389 other location
metastasis

Summary

The purpose of this study is to evaluate the prevalence of 4 or more DNA-repair gene defects in a population of men with metastatic Prostate Cancer (PC) and to use the reported DNA-repair gene defects to assess biomarker eligibility for niraparib interventional studies.

Details
Treatment Saliva, Blood, or Existing Tissue Sample Collection and Analysis, Saliva, Blood, or and/or Archival Tumor Tissue Collection and Analysis
Clinical Study IdentifierNCT03871816
SponsorJanssen Research & Development, LLC
Last Modified on8 January 2021

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age greater than or equal to 18 yrs?
Are you male?
Do you have Metastatic Prostate Cancer?
Do you have any of these conditions: Metastatic Prostate Cancer or Prostate Cancer Metastatic?
Do you have any of these conditions: Prostate Cancer Metastatic or Metastatic Prostate Cancer?
Do you have any of these conditions: Metastatic Prostate Cancer or Prostate Cancer Metastatic?
Do you have any of these conditions: Metastatic Prostate Cancer or Prostate Cancer Metastatic?
Diagnosis of metastatic (Stage IV) prostate cancer (PC), confirmed by either biopsy of a metastatic tumor site or history of localized disease supported by metastatic disease on imaging studies (that is [i.e.], clearly noted in hospital/clinical records)
Signed Informed consent form (ICF)
No condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (for example [e.g.], compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Willing to provide a saliva, blood, and/or archival tumor tissue sample for genomic analysis
No prior poly (adenosine diphosphate [ADP]-ribose) polymerase inhibitor (PARPi) for the treatment of prostate cancer
No prior DNA-repair gene defect test results from a Janssen sponsored interventional trial
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet